Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Purchases $9,999,995.00 in Stock

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Life Sciences Xi L.P. Frazier acquired 588,235 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was bought at an average cost of $17.00 per share, with a total value of $9,999,995.00. Following the acquisition, the insider owned 6,154,213 shares in the company, valued at approximately $104,621,621. This trade represents a 10.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Attovia Therapeutics Stock Down 6.9%

Attovia Therapeutics stock traded down $1.52 during midday trading on Thursday, hitting $20.38. 413,197 shares of the company were exchanged. Attovia Therapeutics, Inc. has a fifty-two week low of $19.63 and a fifty-two week high of $22.79.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.